Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

Nicole L. Yates, Hua Xin Liao, Youyi Fong, Allan DeCamp, Nathan A. Vandergrift, William T. Williams, S. Munir Alam, Guido Ferrari, Zhi Yong Yang, Kelly E. Seaton, Phillip W. Berman, Michael D. Alpert, David T. Evans, Robert J. O'Connell, Donald Francis, Faruk Sinangil, Carter Lee, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal & 11 others Punnee Pitisuttithum, James Tartaglia, Abraham Pinter, Susan Zolla-Pazner, Peter B. Gilbert, Gary J. Nabel, Nelson L. Michael, Jerome H. Kim, David C. Montefiori, Barton F. Haynes, Georgia D. Tomaras

Research output: Contribution to journalArticle

Abstract

HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.

Original languageEnglish (US)
Article number228ra39
JournalScience Translational Medicine
Volume6
Issue number228
DOIs
StatePublished - Mar 19 2014
Externally publishedYes

Fingerprint

HIV Infections
HIV-1
Vaccination
Vaccines
Immunoglobulin G
AIDS Vaccines
Antibodies
Clinical Trials
Fc Receptors
Case-Control Studies
Epitopes
B-Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Yates, N. L., Liao, H. X., Fong, Y., DeCamp, A., Vandergrift, N. A., Williams, W. T., ... Tomaras, G. D. (2014). Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Science Translational Medicine, 6(228), [228ra39]. https://doi.org/10.1126/scitranslmed.3007730

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. / Yates, Nicole L.; Liao, Hua Xin; Fong, Youyi; DeCamp, Allan; Vandergrift, Nathan A.; Williams, William T.; Alam, S. Munir; Ferrari, Guido; Yang, Zhi Yong; Seaton, Kelly E.; Berman, Phillip W.; Alpert, Michael D.; Evans, David T.; O'Connell, Robert J.; Francis, Donald; Sinangil, Faruk; Lee, Carter; Nitayaphan, Sorachai; Rerks-Ngarm, Supachai; Kaewkungwal, Jaranit; Pitisuttithum, Punnee; Tartaglia, James; Pinter, Abraham; Zolla-Pazner, Susan; Gilbert, Peter B.; Nabel, Gary J.; Michael, Nelson L.; Kim, Jerome H.; Montefiori, David C.; Haynes, Barton F.; Tomaras, Georgia D.

In: Science Translational Medicine, Vol. 6, No. 228, 228ra39, 19.03.2014.

Research output: Contribution to journalArticle

Yates, NL, Liao, HX, Fong, Y, DeCamp, A, Vandergrift, NA, Williams, WT, Alam, SM, Ferrari, G, Yang, ZY, Seaton, KE, Berman, PW, Alpert, MD, Evans, DT, O'Connell, RJ, Francis, D, Sinangil, F, Lee, C, Nitayaphan, S, Rerks-Ngarm, S, Kaewkungwal, J, Pitisuttithum, P, Tartaglia, J, Pinter, A, Zolla-Pazner, S, Gilbert, PB, Nabel, GJ, Michael, NL, Kim, JH, Montefiori, DC, Haynes, BF & Tomaras, GD 2014, 'Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination', Science Translational Medicine, vol. 6, no. 228, 228ra39. https://doi.org/10.1126/scitranslmed.3007730
Yates, Nicole L. ; Liao, Hua Xin ; Fong, Youyi ; DeCamp, Allan ; Vandergrift, Nathan A. ; Williams, William T. ; Alam, S. Munir ; Ferrari, Guido ; Yang, Zhi Yong ; Seaton, Kelly E. ; Berman, Phillip W. ; Alpert, Michael D. ; Evans, David T. ; O'Connell, Robert J. ; Francis, Donald ; Sinangil, Faruk ; Lee, Carter ; Nitayaphan, Sorachai ; Rerks-Ngarm, Supachai ; Kaewkungwal, Jaranit ; Pitisuttithum, Punnee ; Tartaglia, James ; Pinter, Abraham ; Zolla-Pazner, Susan ; Gilbert, Peter B. ; Nabel, Gary J. ; Michael, Nelson L. ; Kim, Jerome H. ; Montefiori, David C. ; Haynes, Barton F. ; Tomaras, Georgia D. / Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. In: Science Translational Medicine. 2014 ; Vol. 6, No. 228.
@article{c38fba7f27a04d5f9bee81fe662e6c10,
title = "Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination",
abstract = "HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.",
author = "Yates, {Nicole L.} and Liao, {Hua Xin} and Youyi Fong and Allan DeCamp and Vandergrift, {Nathan A.} and Williams, {William T.} and Alam, {S. Munir} and Guido Ferrari and Yang, {Zhi Yong} and Seaton, {Kelly E.} and Berman, {Phillip W.} and Alpert, {Michael D.} and Evans, {David T.} and O'Connell, {Robert J.} and Donald Francis and Faruk Sinangil and Carter Lee and Sorachai Nitayaphan and Supachai Rerks-Ngarm and Jaranit Kaewkungwal and Punnee Pitisuttithum and James Tartaglia and Abraham Pinter and Susan Zolla-Pazner and Gilbert, {Peter B.} and Nabel, {Gary J.} and Michael, {Nelson L.} and Kim, {Jerome H.} and Montefiori, {David C.} and Haynes, {Barton F.} and Tomaras, {Georgia D.}",
year = "2014",
month = "3",
day = "19",
doi = "10.1126/scitranslmed.3007730",
language = "English (US)",
volume = "6",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "228",

}

TY - JOUR

T1 - Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

AU - Yates, Nicole L.

AU - Liao, Hua Xin

AU - Fong, Youyi

AU - DeCamp, Allan

AU - Vandergrift, Nathan A.

AU - Williams, William T.

AU - Alam, S. Munir

AU - Ferrari, Guido

AU - Yang, Zhi Yong

AU - Seaton, Kelly E.

AU - Berman, Phillip W.

AU - Alpert, Michael D.

AU - Evans, David T.

AU - O'Connell, Robert J.

AU - Francis, Donald

AU - Sinangil, Faruk

AU - Lee, Carter

AU - Nitayaphan, Sorachai

AU - Rerks-Ngarm, Supachai

AU - Kaewkungwal, Jaranit

AU - Pitisuttithum, Punnee

AU - Tartaglia, James

AU - Pinter, Abraham

AU - Zolla-Pazner, Susan

AU - Gilbert, Peter B.

AU - Nabel, Gary J.

AU - Michael, Nelson L.

AU - Kim, Jerome H.

AU - Montefiori, David C.

AU - Haynes, Barton F.

AU - Tomaras, Georgia D.

PY - 2014/3/19

Y1 - 2014/3/19

N2 - HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.

AB - HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.

UR - http://www.scopus.com/inward/record.url?scp=84899087118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899087118&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3007730

DO - 10.1126/scitranslmed.3007730

M3 - Article

VL - 6

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 228

M1 - 228ra39

ER -